CDK4/6 inhibitors prolong OS

被引：0
|
作者：
David Killock
机构：
[1] Nature Reviews Clinical Oncology,
来源：
Nature Reviews Clinical Oncology | 2019年 / 16卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：722 / 722
相关论文
共 50 条
  • [21] The major human metabolites of abemaciclib are inhibitors of CDK4 and CDK6
    Burke, Teresa
    Torres, Raquel
    McNulty, Ann
    Dempsey, Jack
    Kolis, Stanley
    Kulanthaivel, Palaniappan
    Beckmann, Richard
    CANCER RESEARCH, 2016, 76
  • [22] CDK6 overexpression promotes resistance to CDK4/6 inhibitors in breast cancer
    Li, Qing
    Razavi, Pedram
    Li, Zhiqiang
    Paula, Arnaud F. Da Cruz
    Brogi, Edi
    Scaltriti, Maurizio
    Reis-Filho, Jorge S.
    Chandarlapaty, Sarat
    CANCER RESEARCH, 2019, 79 (13)
  • [23] Mechanisms and Implications of CDK4/6 Inhibitors for the Treatment of NSCLC
    Zhang, Jinmeng
    Xu, Dayu
    Zhou, Yue
    Zhu, Zhengfei
    Yang, Xi
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [24] Improving Breast Cancer Therapy With CDK4/6 Inhibitors
    Jaganathan, Hamsa
    Overstreet, Karen
    Reed, Elizabeth
    CLINICAL BREAST CANCER, 2014, 14 (06) : 379 - 380
  • [25] Development of CDK4/6 Inhibitors: A Five Years Update
    Ammazzalorso, Alessandra
    Agamennone, Mariangela
    De Filippis, Barbara
    Fantacuzzi, Marialuigia
    MOLECULES, 2021, 26 (05):
  • [26] Predicting Response to CDK4/6 Inhibitors in Breast Cancer
    Schultz, Emily
    Hamilton, Deanna
    Wang, Jianxin
    Witkiewicz, Agnieszka
    LABORATORY INVESTIGATION, 2023, 103 (03) : S208 - S208
  • [27] CDK4/6 inhibitors in breast cancer: spotting the difference
    Perez-Garcia, Jose Manuel
    Cortes, Javier
    Llombart-Cussac, Antonio
    NATURE MEDICINE, 2021, 27 (11) : 1868 - 1869
  • [28] CDK4/6 inhibitors: a novel strategy for tumor radiosensitization
    Yang, Yilan
    Luo, Jurui
    Chen, Xingxing
    Yang, Zhaozhi
    Mei, Xin
    Ma, Jinli
    Zhang, Zhen
    Guo, Xiaomao
    Yu, Xiaoli
    JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 2020, 39 (01)
  • [29] Senescence as a therapeutically relevant response to CDK4/6 inhibitors
    Wagner, Verena
    Gil, Jesus
    ONCOGENE, 2020, 39 (29) : 5165 - 5176
  • [30] Senescence as a therapeutically relevant response to CDK4/6 inhibitors
    Verena Wagner
    Jesús Gil
    Oncogene, 2020, 39 : 5165 - 5176
12345